Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02301988
Recruitment Status : Completed
First Posted : November 26, 2014
Results First Posted : September 20, 2018
Last Update Posted : October 17, 2018
Sponsor:
Collaborator:
SOLTI Breast Cancer Research Group
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This is a randomized, double-blind, placebo-controlled, multicenter, pre-operative Phase II study designed to estimate the efficacy of ipatasertib combined with paclitaxel chemotherapy versus placebo combined with paclitaxel chemotherapy in women with Stage Ia - IIIa triple-negative breast adenocarcinoma. The anticipated time on study treatment is 12 weeks.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Ipatasertib Drug: Paclitaxel Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 151 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer
Actual Study Start Date : February 17, 2015
Actual Primary Completion Date : August 2, 2017
Actual Study Completion Date : August 2, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: Ipatasertib + Paclitaxel
Participants will receive ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).
Drug: Ipatasertib
Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
Other Name: GDC-0068

Drug: Paclitaxel
Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion QW for 3 cycles.

Placebo Comparator: Placebo + Paclitaxel
Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
Drug: Paclitaxel
Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion QW for 3 cycles.

Drug: Placebo
Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.




Primary Outcome Measures :
  1. Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants) [ Time Frame: Surgery visit (at approximately Weeks 14 to 19) ]
    pCR was defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes.

  2. Percentage of Participants With pCR in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in Participants Who Have Phosphatase and Tensin Homolog [PTEN]-Low Tumors) [ Time Frame: Surgery visit (at approximately Weeks 14 to 19) ]
    pCR was defined by ypT0/Tis ypN0 in the AJCC Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes.


Secondary Outcome Measures :
  1. Percentage of Participants With pCR in Breast as Defined by ypT0/Tis in the American Joint Committee on Cancer Staging System (in All Participants) [ Time Frame: Surgery visit (at approximately Weeks 14 to 19) ]
    pCR was defined by ypT0/Tis in the AJCC Staging System with the following determination for breast by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue.

  2. Percentage of Participants With pCR in Breast as Defined by ypT0/Tis in the American Joint Committee on Cancer Staging System (in Participants Who Have PTEN-low Tumors) [ Time Frame: Surgery visit (at approximately Weeks 14 to 19) ]
    pCR was defined by ypT0/Tis in the AJCC Staging System with the following determination for breast by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue.

  3. Percentage of Participants With Objective Tumor Response by Magnetic Resonance Imaging (MRI), As Assessed by Investigator Per the Modified Response Evaluation Criteria in Solid Tumors (RECIST) (in All Participants) [ Time Frame: Screening up to disease progression or death (assessed at screening, pre-surgical visit [approximately Weeks 10-12], early termination visit [up to Week 16]) ]
    Objective tumor response (OR) was based on criteria related to changes in size of target lesions according to modified RECIST. Target lesions were selected on the basis of their size (lesions with the longest diameter) as well as the feasibility of reproducible repeated measurements. OR was the sum of complete response (CR) and partial response (PR). CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

  4. Percentage of Participants With Objective Tumor Response by MRI, As Assessed by Investigator Per Modified RECIST (in Participants Who Have PTEN-low Tumors) [ Time Frame: Screening up to disease progression or death (assessed at screening, pre-surgical visit [approximately Weeks 10-12], early termination visit [up to Week 16]) ]
    ORR was based on criteria related to changes in size of target lesions according to modified RECIST. Target lesions were selected on the basis of their size (lesions with the longest diameter) as well as the feasibility of reproducible repeated measurements. ORR was the sum of complete response (CR) and partial response (PR). CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

  5. Percentage of Participants With pCR in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in Participants Who Are Akt Diagnostic Positive [Dx+]) [ Time Frame: Surgery visit (at approximately Weeks 14 to 19) ]
    pCR was defined by ypT0/Tis ypN0 in the AJCC Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes.

  6. Percentage of Participants With pCR in Breast as Defined by ypT0/Tis in the American Joint Committee on Cancer Staging System (in Participants Who Are Akt Dx+) [ Time Frame: Surgery visit (at approximately Weeks 14 to 19) ]
    pCR was defined by ypT0/Tis in the AJCC Staging System with the following determination for breast by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue.

  7. Percentage of Participants With pCR According to American Joint Committee on Cancer Staging System, by Breast Cancer Subtype [ Time Frame: Surgery visit (at approximately Weeks 14 to 19) ]
    pCR was defined by ypT0/Tis in the AJCC Staging System with the following determination for breast subtypes by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue. The intrinsic molecular subtypes of breast cancer included here are luminal A (LumA), Her-2, basal-like, normal and unknown.

  8. Percentage of Participants With Response to Undergoing Breast Conserving Surgery (BCS) Among Participants With T2 or T3 Tumors [ Time Frame: Surgery visit (at approximately Weeks 14 to 19) ]
    After neoadjuvant treatment, the number of patients who is appropriate for breast conserving surgery is reported as a measure of efficacy of the treatment to shrink the tumor enough for patients to benefit from less aggressive surgical management. Breast-conserving surgery was defined as removal of part of the breast tissue during surgery. T2 or T3 in the AJCC Staging System were defined as follows: T2: tumor was more than 2 centimeter (cm) but no more than 5 cm across; T3: tumor was larger than 5 cm across.

  9. Percentage of Participants With Response to Conversion to BCS Among Participants With T2 or T3 Tumors [ Time Frame: From screening to surgery visit (at approximately Weeks 14 to 19) ]
    After neoadjuvant treatment, the number of patients who is appropriate for breast conserving surgery is reported as a measure of efficacy of the treatment to shrink the tumor enough for patients to benefit from less aggressive surgical management. Breast-conserving surgery was defined as removal of part of the breast tissue during surgery. T2 or T3 in the AJCC Staging System were defined as follows: T2: tumor was more than 2 centimeter (cm) but no more than 5 cm across; T3: tumor was larger than 5 cm across.

  10. Percentage of Participants With Adverse Events [ Time Frame: Screening up to Week 24 ]
    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

  11. Plasma Concentrations of Ipatasertib on Day 1 and Day 8 [ Time Frame: 0.5 and 4 hours post dose on Day 1 of Cycle 1, 166 and 170 hours post dose from Day 1 of Cycle 1 (Cycle length = 28 days) ]
    Plasma samples for pharmacokinetic characterization was collected at various timepoints in all participants.

  12. Minimum Observed Plasma Concentration (Cmin) of Ipatasertib [ Time Frame: 0.5 and 4 hours post dose on Day 1 of Cycle 1, 166 and 170 hours post dose from Day 1 of Cycle 1 (Cycle length = 28 days) ]
    Plasma samples for pharmacokinetic characterization was collected on Day 1 and Day 8 in all participants.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Premenopausal or postmenopausal women
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Histologically documented, Stage Ia to operable Stage IIIa, triple-negative carcinoma of the breast with primary tumor greter than or equal to (>/=) 1.5 centimeters (cm) in largest diameter (cT1-3) by MRI
  • Adequate hematologic and organ function within 14 days before the first study treatment
  • Availability of tumor tissue from formalin-fixed, paraffin-embedded (FFPE) core biopsy of breast primary tumor
  • For female participants of childbearing potential, agreement to use highly effective form(s) of contraception for the duration of the study and for at least 6 months after last dose of study treatment

Exclusion Criteria:

  • Known human epidermal growth factor 2 (HER2)-positive, estrogen receptor (ER)-positive, or progesterone receptor (PgR)-positive breast cancer
  • Any prior treatment for the current primary invasive breast cancer
  • Participants with cT4 or cN3 stage breast tumors
  • Metastatic (Stage IV) breast cancer
  • Bilateral invasive breast cancer
  • Multicentric breast cancer
  • Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02301988


  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
Arizona Oncology Associates, PC-CASA
Tucson, Arizona, United States, 85704
United States, California
Sansum Medical Clinic, Inc.
Santa Barbara, California, United States, 93105
United States, Colorado
Rocky Mountain Cancer Center - Lakewood (West)
Lakewood, Colorado, United States, 80228
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Mass General/North Shore Cancer
Danvers, Massachusetts, United States, 01923
United States, Nebraska
Nebraska Cancer Specialists; Oncology Hematology West, PC
Omaha, Nebraska, United States, 68130
United States, North Carolina
Carolinas Healthcare System
Charlotte, North Carolina, United States, 28208
United States, Oregon
Northwest Cancer Specialists - Portland (NE Hoyt St)
Portland, Oregon, United States, 97213
United States, South Carolina
Roper Bon Secours St. Francis Cancer Center
Charleston, South Carolina, United States, 29414
United States, Texas
Texas Oncology
Austin, Texas, United States, 78705
Texas Oncology Cancer Center
Austin, Texas, United States, 78731
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States, 75246
Texas Oncology - Houston (Gessner)
Houston, Texas, United States, 77024
Texas Oncology-Tyler
Irving, Texas, United States, 75063
South Texas Cancer Center - McAllen
McAllen, Texas, United States, 78503
United States, Washington
Northwest Medical Specialties, PLLC
Tacoma, Washington, United States, 98405
Portugal
IPO de Lisboa; Servico de Oncologia Medica
Lisboa, Portugal, 1099-023
Hospital Beatriz Angelo; Departamento de Oncologia
Loures, Portugal, 2674-514
IPO do Porto; Servico de Oncologia Medica
Porto, Portugal, 4200-072
Spain
Hospital Universitario Son Espases
Palma De Mallorca, Islas Baleares, Spain, 07014
Hospital Son Llatzer; Servicio de Oncologia
Palma de Mallorca, Islas Baleares, Spain, 07198
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
Santiago de Compostela, LA Coruña, Spain, 15706
Hospital Universitari de Lleida Arnau de Vilanova
Lleida, Lerida, Spain, 25198
Hospital Universitario Fundación Alcorcón
Alcorcón (Madrid), Madrid, Spain, 28922
Hospital Rey Juan Carlos; Pharmacy
Mostoles, Madrid, Spain, 28933
Hospital Regional Universitario Carlos Haya; hospital Materno Infantil, servicio de Farmacia
Málaga, Malaga, Spain, 29011
Hospital Universitario Virgen Macarena
Seville, Sevilla, Spain, 41071
Hospital Universitari Sant Joan de Reus; Servicio de Oncologia
Reus, Tarragona, Spain, 43204
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, Spain, 08035
Institut Catala d Oncologia Hospital Duran i Reynals
Barcelona, Spain, 08908
Hospital San Pedro De Alcantara; Servicio de Oncologia
Caceres, Spain, 10003
Hospital Provincial de Castellon; Servicio de Oncologia
Castellon, Spain, 12002
Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia
Girona, Spain, 17007
Centro Oncologico MD Anderson International Espana
Madrid, Spain, 28033
Fundacion Jimenez Diaz; Servicio de Oncologia
Madrid, Spain, 28040
Hospital Universitario Clínico San Carlos
Madrid, Spain, 28040
Hospital Universitario 12 de Octubre; Servicio de Oncologia
Madrid, Spain, 28041
Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica
Madrid, Spain, 28050
Hospital Quiron de Madrid; Servicio de Oncologia
Madrid, Spain, 28223
Hospital Universitario de Fuenlabrada; Servicio de Oncologia
Madrid, Spain, 28943
Hospital Virgen del Rocio
Sevilla, Spain, 41013
Hospital Clinico Universitario; Oncologia
Valencia, Spain, 46010
Sponsors and Collaborators
Genentech, Inc.
SOLTI Breast Cancer Research Group
Investigators
Layout table for investigator information
Study Director: Clinical Trials Genentech, Inc.
  Study Documents (Full-Text)

Documents provided by Genentech, Inc.:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT02301988     History of Changes
Other Study ID Numbers: GO29505
2014-003029-16 ( EudraCT Number )
First Posted: November 26, 2014    Key Record Dates
Results First Posted: September 20, 2018
Last Update Posted: October 17, 2018
Last Verified: September 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action